<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/chromadex-nasdaqcdxc-trading-5-1-higher.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T22:18:41+00:00"/>
    <meta property="og:title" content="Chromadex (NASDAQ:CDXC) Trading 5.1% Higher"/>
    <meta property="og:description" content="Chromadex Corp (NASDAQ:CDXC) shares traded up 5.1% during mid-day trading on Tuesday . The stock traded as high as $3.52 and last traded at $3.48, 374,600 shares traded hands during mid-day trading. An increase of 71% from the average session volume of 219,313 shares. The stock had previously closed at $3.31. Several analysts have issued […]"/>
  </head>
  <body>
    <article>
      <h1>Chromadex (NASDAQ:CDXC) Trading 5.1% Higher</h1>
      <address><time datetime="2019-11-19T22:18:41+00:00">19 Nov 2019, 22:18</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/chromadex-corp-logo.jpg"/>
      </figure>
      <p>Chromadex Corp (NASDAQ:CDXC) shares traded up 5.1% during mid-day trading on Tuesday . The stock traded as high as $3.52 and last traded at $3.48, 374,600 shares traded hands during mid-day trading. An increase of 71% from the average session volume of 219,313 shares. The stock had previously closed at $3.31.</p>
      <p>Several analysts have issued reports on the company. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=CDXC">ValuEngine</a> lowered Chromadex from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Oppenheimer began coverage on Chromadex in a research note on Tuesday, October 15th. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded Chromadex from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Chromadex presently has a consensus rating of “Buy” and an average target price of $6.00.</p>
      <p>The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.41 and a current ratio of 3.30. The company has a market capitalization of $189.46 million, a P/E ratio of -5.70 and a beta of 1.35. The business has a 50 day moving average of $3.23 and a 200-day moving average of $4.02.</p>
      <p>Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). Chromadex had a negative return on equity of 137.97% and a negative net margin of 74.55%. The company had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.66 million. As a group, equities analysts forecast that Chromadex Corp will post -0.51 EPS for the current fiscal year.</p>
      <p>In related news, CEO Robert N. Fried acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $32,000.00. Insiders own 11.60% of the company’s stock.</p>
      <p>Several large investors have recently added to or reduced their stakes in the stock. Uniplan Investment Counsel Inc. bought a new stake in shares of Chromadex during the 2nd quarter valued at $3,279,000. BlackRock Inc. raised its stake in shares of Chromadex by 15.4% during the 2nd quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock valued at $10,410,000 after purchasing an additional 298,126 shares during the period. Northern Trust Corp raised its stake in shares of Chromadex by 0.7% during the 2nd quarter. Northern Trust Corp now owns 416,911 shares of the company’s stock valued at $1,939,000 after purchasing an additional 3,090 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Chromadex by 8.1% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock valued at $425,000 after purchasing an additional 6,880 shares during the period. Finally, Tieton Capital Management LLC raised its stake in shares of Chromadex by 5.1% during the 2nd quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock valued at $6,150,000 after purchasing an additional 64,680 shares during the period. Institutional investors own 18.78% of the company’s stock.</p>
      <p><b>About Chromadex</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/CDXC/">NASDAQ:CDXC</a>)</p>
      <p>ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.</p>
      <p>See Also: <a href="https://www.marketbeat.com/market-data/52-week-lows/">52-Week High/Low</a></p>
    </article>
  </body>
</html>